VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma

Peter Preis, W. Scheithauer, E. Fritz, C. Zielinski, I. Kuehrer, A. Cortelezzi, E. Polli, L. Raldini, R. Pirker, A. Kriegisch, H. Ludwig

Research output: Contribution to journalArticle

Abstract

Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalOncology Research and Treatment
Volume12
Issue number1
DOIs
Publication statusPublished - 1989

Fingerprint

Multiple Myeloma
Interferon-alpha
Interferons
Drug Therapy
Melphalan
Vincristine
Prednisolone
Combination Drug Therapy
Cyclophosphamide
Survival
Therapeutics

Keywords

  • Combinations treatment
  • Interferon-alpha-2
  • Multiples Myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. / Preis, Peter; Scheithauer, W.; Fritz, E.; Zielinski, C.; Kuehrer, I.; Cortelezzi, A.; Polli, E.; Raldini, L.; Pirker, R.; Kriegisch, A.; Ludwig, H.

In: Oncology Research and Treatment, Vol. 12, No. 1, 1989, p. 27-29.

Research output: Contribution to journalArticle

Preis, P, Scheithauer, W, Fritz, E, Zielinski, C, Kuehrer, I, Cortelezzi, A, Polli, E, Raldini, L, Pirker, R, Kriegisch, A & Ludwig, H 1989, 'VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma', Oncology Research and Treatment, vol. 12, no. 1, pp. 27-29. https://doi.org/10.1159/000216593
Preis, Peter ; Scheithauer, W. ; Fritz, E. ; Zielinski, C. ; Kuehrer, I. ; Cortelezzi, A. ; Polli, E. ; Raldini, L. ; Pirker, R. ; Kriegisch, A. ; Ludwig, H. / VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. In: Oncology Research and Treatment. 1989 ; Vol. 12, No. 1. pp. 27-29.
@article{b1c6d08f92ad45f9a6fa741e1cc7e9a4,
title = "VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma",
abstract = "Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9{\%}) responses as compared to 19/27 (70.4{\%}) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.",
keywords = "Combinations treatment, Interferon-alpha-2, Multiples Myeloma",
author = "Peter Preis and W. Scheithauer and E. Fritz and C. Zielinski and I. Kuehrer and A. Cortelezzi and E. Polli and L. Raldini and R. Pirker and A. Kriegisch and H. Ludwig",
year = "1989",
doi = "10.1159/000216593",
language = "English",
volume = "12",
pages = "27--29",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma

AU - Preis, Peter

AU - Scheithauer, W.

AU - Fritz, E.

AU - Zielinski, C.

AU - Kuehrer, I.

AU - Cortelezzi, A.

AU - Polli, E.

AU - Raldini, L.

AU - Pirker, R.

AU - Kriegisch, A.

AU - Ludwig, H.

PY - 1989

Y1 - 1989

N2 - Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.

AB - Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.

KW - Combinations treatment

KW - Interferon-alpha-2

KW - Multiples Myeloma

UR - http://www.scopus.com/inward/record.url?scp=0024587844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024587844&partnerID=8YFLogxK

U2 - 10.1159/000216593

DO - 10.1159/000216593

M3 - Article

C2 - 2654788

AN - SCOPUS:0024587844

VL - 12

SP - 27

EP - 29

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 1

ER -